Complication rates in Sentinel Lymph Node Biopsy for Melanoma

Malignant melanoma is the 5th most common cancer in the UK, with 12, 818 new cases diagnosed in 2010 [1]. Surgery remains fundamental to treatment. Sentinel lymph node biopsy (SLNB) is indicated for those patients with a clinically negative nodal basin and a primary melanoma with a Breslow thickness of >1mm. The evidence for Completion Lymph Node Dissection (CLND) is under review with the final results of MSLT II available in 2022. Complication rates in the literature range between 5-10% [2-3]. The authors aimed to ascertain the risk of complications following SLNB in a regional unit.

from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/1T2JSrA
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1Ymejdy
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/1QqUdQh
via IFTTT